For your patients who have congenital hemophilia
A or B with inhibitors (CHwI), it’s time to help them
Spread their wings
Experience—30 years of research and long-term clinical experience1,a
Effectiveness—proven efficacy in bleed control and surgery in 4 conditions2
Portability—room temperature stable for fast access to treatment2
Speed—fast reconstitution and infusion time leading to fast activity2,3
Safety—recombinant safety and a low rate of thrombotic adverse events2,4,b
a
Compassionate use, also known as expanded access, began enrolling in 1989;
FDA approval received in 1999.
b
In people with hemophilia A or B with inhibitors
Visit NovoSevenRT.com/HCP
today to learn more.
Chase, 5 years old, lives with
CHwI, and loves anything that
has to do with cars, planes, or
playing golf.